SHM Announces Support for Nomination of Dr. Scott Gottlieb as FDA Commissioner

Nomination Affirms Increased Importance of Hospitalist Voice in Shaping Healthcare Policy

On behalf of more than 50,000 practicing hospitalists nationwide, the Society of Hospital Medicine (SHM) strongly supports the nomination of Scott Gottlieb, MD, as Commissioner of the Food and Drug Administration (FDA) – a move that affirms the growing importance of the hospitalist perspective in public policy.

“As a hospitalist and an active member of the society and its Public Policy Committee, Dr. Gottlieb has shown an unwavering respect for physician autonomy and is a champion for putting the patient first in the delivery of high quality care,” says Ron Greeno, MD, MHM, SHM President-elect and Chair of the Public Policy Committee. “As FDA Commissioner, Dr. Gottlieb will bring a demonstrated commitment to public service coupled with the quality-driven, results-oriented mindset of a hospitalist.”

During his time with SHM, Dr. Gottlieb has been heavily involved with the society’s efforts to empower hospitalists and the overall healthcare system to deliver quality, patient-centered care at lower cost. His public service to the government in various healthcare-related roles, including his tenure at the Centers for Medicare and Medicaid Services (CMS) as Senior Policy Adviser to the Administrator, Senior Adviser for Medical Technology, Director of Medical Policy Development and Deputy Commissioner for Medical and Scientific Affairs at the FDA, will provide him with the deep and diverse experience that the role of FDA Commissioner demands.